Medscape is available in 5 Language Editions – Choose your Edition here.


Dermatologic Manifestations of Homocystinuria

  • Author: Janette Baloghova, MD, PhD; Chief Editor: Dirk M Elston, MD  more...
Updated: Sep 22, 2015


Homocystinuria is an inherited autosomal recessive defect in methionine metabolism that is caused by a deficiency in cystathionine synthase. This defect leads to a multisystemic disorder of the connective tissue, muscles, CNS, and cardiovascular system. Homocystinuria represents a group of hereditary metabolic disorders characterized by an accumulation of homocysteine in the serum and an increased excretion of homocysteine in the urine. Note the figure below.

Simplified picture showing homocysteine involvemen Simplified picture showing homocysteine involvement in different metabolic pathways, as well as the role of vitamins B-6, B-12, and folate as a co-factors in this pathway.

In 1960, the first case of homocystinuria was reported from Northern Ireland. The patient was initially described as having an unusual case of Marfan syndrome with renal abnormalities at age 7 years. He had recovered from acute glomerulonephritis at age 6 years and was found to be hypertensive the following year. The patient was mentally slow and thin and had fair hair, pale skin, and flushed cheeks. He had arachnodactyly, dolichostenomelia, pes cavus, a high arched palate, and bilaterally dislocated lenses. At age 10 years, the patient's urine was found to contain a large quantity of homocysteine; urinalysis results for the nitroprusside cyanide test were positive. The boy's left eye was enucleated because of a staphylococcal infection that occurred after acute pupillary-block glaucoma developed. His right lens became dislocated into the anterior chamber and had to be removed.

The patient's blood pressure readings normalized after his left kidney was removed when he was aged 13 years. Thick-walled internal arteries were noted at histologic examination. When pyridoxine supplementation was initiated at age 18 years, the patient's plasma homocysteine levels decreased below the reference range. Daily folic acid supplementation was added 1 year later because his plasma folate level was low. At age 20 years, the patient had a perforated duodenal ulcer. Chest pain occurred at age 27 years and recurred at age 34 years. The chest pain was considered to be angina and was successfully treated. At age 50 years, the patient's plasma homocysteine levels still remained low. The patient developed acute gout, which responded to indomethacin therapy.



Homocysteine is metabolized by means of 2 pathways: remethylation and transsulfuration.

The remethylation pathway comprises 2 intersecting biochemical pathways and results in the transfer of a methyl group (CH3) to homocysteine from methylcobalamin, which receives its methyl group from S-adenosylmethionine (SAM), from 5-methyltetrahydrofolate (an active form of folic acid), or from betaine (trimethylglycine). Methionine can then be used to produce SAM, the body's universal methyl donor, which participates in several other key metabolic pathways, including the methylation of DNA and myelin.

The transsulfuration pathway of methionine/homocysteine degradation produces the amino acids cysteine and taurine. This pathway is dependent on adequate intake of vitamin B-6 and the hepatic conversion of vitamin B-6 into its active form, pyridoxal-5'-phosphate (P5P). The amino acid serine, which is a downstream metabolite generated from betaine via the homocysteine remethylation pathway is another necessary step.

Folate and vitamin B-12 are required for the remethylation of homocysteine to methionine. Findings from experimental studies have indicated that thyroid hormones affect folate metabolism. The observation that methylenetetrahydrofolate reductase is increased in hyperthyroidism and decreased in hypothyroidism may be relevant to the relationship between plasma homocysteine levels and thyroid status.

Women tend to have lower basal levels of homocysteine than do men, and neither contraceptives nor hormone replacement therapy seems to significantly alter the levels. Homocysteine concentrations are higher in postmenopausal women than in premenopausal women.

On the basis of the type of homocystinuria, the following 3 nosologic units are distinguished:

  • Homocystinuria can be caused by the deficiency of cystathionine synthase. This is the classic form. The gene for this deficiency is located on band 21q22.3. This unit includes the following forms: vitamin B-6 sensitivity (1.5% enzymatic activity), vitamin B-6 resistance (0% enzymatic activity), an intermediate variant, and a benign variant.
  • Homocystinuria can be caused by insufficient vitamin B-12 synthesis resulting from a defect in the remethylation of homocysteine to methionine; methylmalonic aciduria is present.
  • Homocystinuria can be caused by a deficiency in methylenetetrahydrofolate reductase. The methionine level is in the reference range.

Urine methionine and homocysteine levels are elevated because of deficient levels of cystathionine beta-synthase. In addition to this, at least 7 causes of homocystinuria are known: (1) defect in vitamin B-12 metabolism, (2) deficiency in N -5,10-methylenetetrahydrofolate reductase, (3) selective intestinal malabsorption of vitamin B-12, (4) homocystinuria responsive to vitamin B-12 (cobalamin [cbl] type E), (5) methylcobalamin deficiency with cbl type G, (6) type 2 vitamin B-12 metabolic defect, and (7) transcobalamin II deficiency.

The basis of the disease is a defect of the gene coding for L-serine dehydratase cystathionine synthase, which converts homocysteine and serine into cystathionine. Deficient activity of this enzyme has been demonstrated in liver extracts, in brain tissue, and in cultured skin fibroblasts and lymphocytes. The deficiency leads to an accumulation of homocysteine and methionine and to its conversion into homocysteine, which is excreted in the urine (Legal test results are positive). Alternatively, methionine is reformed and detectable in appreciable amounts in the urine and serum. The accumulation of homocysteine leads to damage of the collagen and elastic fibers. The binding of homocysteine to lysine residues results in the formation of thiazine bonds.

DL-homocysteine inhibits the production of tyrosinase, which is the major pigment enzyme. Increased concentrations of the methionine metabolite are toxic to the nervous system. Histologic analysis of brain tissue specimens from patients with homocystinuria reveals local foci of gliosis and necrosis.

In 1985, Mudd et al studied hybrid cells of human fibroblasts with normal cystathionine beta-synthase activity and hamster cells without enzyme activity and found that enzyme activity was co-segregated with chromosome 21.[1] Two other enzymes involved in sulfur amino acid metabolism have been mapped: 5-methyltetrahydrofolate and L-homocysteine S-methyltransferase are mapped to chromosome 1, and cystathionase is mapped to chromosome 16.[2]

In cases of genetic deletion and partial trisomy, the levels of activity are consistent with the locus of cystathionine beta-synthase (CBS) between bands 21q22.1 and 21q21. As reported in the study of fibroblasts, 3 types of cystathionine synthetase deficiency exist; these include types with reduced activity and normal affinity for P5P and types with reduced activity and reduced affinity for the cofactor.

The human CBS gene spans more than 30 kilobases and contains 19 exons. Three different 5' untranslated regions exist in the gene.

Molecular analysis of the methionine synthase reductase (MTRR) gene in one patient reveals compound heterozygosity for a transition c.1459G>A (G487R) and a 2–base pair (bp) insertion (c.1623-1624insTA). Another patient was homozygous for a 140-bp insertion (c.903-904ins140). The insertion is caused by a T>C transition within intron 6 of the MTRR gene, which presumably leads to activation of an exon splicing enhancer. These findings support the concept that this disorder is caused by mutations in the MTRR gene.

Four different mutations were identified in patients in the United Kingdom (c.374G>A, R125Q; c.430G>A, E144K; c.833T>C, I278T; c.919G>A, G307S) and 8 mutations were identified in patients from the United States (c.341C>T, A114V; c.374G>A, R125Q; c.785C>T, T262M; c.797G>A, R266K; c.833T>C, I278T; c.919G>A, G307S; g.13217A>C (del ex 12); c.1330G>A, D444N).[3] The I278T was the predominant mutation in both populations. The spectrum of mutations observed in patients from the United Kingdom and the United States is closer to that observed in Northern Europe and bears less resemblance to that observed in Ireland.

Severe deficiency of glycine N -methyltransferase (GNMT) activity due to apparent homozygosity for a novel mutation in the gene encoding this enzyme that changes asparagine-140 to serine can be another cause of hypermethioninemia.[4]

To date, 130 pathogenic mutations have been recognized in the CBS gene. In 2004, Orendae examined 10 independent alleles in Polish patients with cystathionine beta-synthase deficiency.[5] They detected 4 already described mutations (c.1224-2A>C, c.684C>A, c.833T>C, and c.442G>A) and 2 novel mutations (c.429C>G and c.1039+1G>T). The pathogenicity of the novel mutations was demonstrated by expression in Escherichia coli. This is the first published communication on mutations leading to cystathionine beta-synthase deficiency in Poland.

Fibrillin-1 is a 350-kd calcium-binding protein that assembles to form 10- to 12-nm microfibrils in the extracellular matrix. The structure of fibrillin-1 is dominated by 2 types of disulfide-rich motifs, the calcium-binding epidermal growth factorlike and transforming growth factor beta binding proteinlike domains. Disruption of fibrillin-1 domain structure and function contributes to the pathogenic mechanisms of homocystinuria.[6]

Methylmalonic aciduria and homocystinuria, combined methylmalonic aciduria and homocystinuria (cblC) type, is the most frequent inborn error of vitamin B-12 metabolism. The gene responsible for cblC, MMACHC, has been identified. Several observations on ethnic origins were noted: the c.331C>T mutation is seen in Cajun and French-Canadian patients and the c.394C>T mutation is common in the Asiatic-Indian/Pakistani/Middle Eastern populations. The recognition of phenotype-genotype correlations and the association of mutations with specific ethnicities will be useful for identification of disease-causing mutations in cblC patients, for carrier detection, and for prenatal diagnosis in families in which mutations are known.[7, 8, 9]

Homozygosity or compound heterozygosity for the c.833T>C transition (p.I278 T) in the cystathionine beta-synthase (CBS) gene represents the most common cause of pyridoxine-responsive homocystinuria in Western Eurasians. However, the frequency of the pathogenic c.833C allele, as observed in healthy newborns from several European countries (q(c.833C) approximately equals 3.3 X 10-3), is approximately 20-fold higher than expected on the basis of the observed number of symptomatic homocystinuria patients carrying this mutation (q(c.833C) approximately equals 0.18 X 10-3), implying clinical underascertainment.

The cblD gene is localized to 2q23.2, and a candidate gene, designated MMADHC (methylmalonic aciduria, cblD type, and homocystinuria), was identified in this region. Transfection of wild-type MMADHC rescued the cellular phenotype, and the functional importance of mutant alleles was shown by means of transfection with mutant constructs. The predicted MMADHC protein has sequence homology with a bacterial ATP-binding cassette transporter and contains a putative cobalamin-binding motif and a putative mitochondrial targeting sequence. Mutations in a gene designated MMADHC are responsible for the cblD defect in vitamin B-12 metabolism. Various mutations are associated with each of the 3 biochemical phenotypes of the disorder.[10]

Using data from 7038 Hordaland Homocysteine Study participants, tCys concentrations show a strong positive association with body mass index, mediated through fat mass. The link between cysteine and lipid metabolism deserves further investigation.[11]

The common polymorphism of the MTHFR gene, c.677C>T, a known risk factor for elevated plasma homocysteine levels, occurs frequently in the white persons. The sequence alteration c.677C>T combined with severe MTHFR mutations in a compound heterozygous state may lead to moderate biochemical and clinical abnormalities, exceeding those attributed to the c.677TT genotype, and might require, in addition to folate substitution, further therapy to normalize homocysteine levels.[12, 13]

Jakubowski et al showed that plasma N -Hcy-protein levels are significantly elevated in CBS - and MTHFR -deficient patients and that CBS -deficient patients have significantly elevated plasma levels of prothrombotic N -Hcy-fibrinogen.[14] These results provide a possible explanation for the increased atherothrombosis observed in CBS -deficient patients.

Homocysteine is readily oxidized in plasma to form homocystine- and homocysteine-mixed disulfides. This oxidation has been correlated with reactive oxygen species generation. Homocysteine can stimulate reactive oxygen species formation in a number of different cell types, such as splenic B lymphocytes, mesangial cells, monocytes, and vascular smooth muscle cells. The oxidative stress might participate, at least in part, in the pathophysiology of homocystinuria. Homocysteine has been found to induce neurological dysfunction via oxidative stress. The cytotoxicity of homocysteine has been reported to be mitigated by antioxidants like N -acetyl cysteine, vitamin E, or vitamin C. The cells from homocystinuria patients with defects in the remethylation pathway showed high reactive oxygen species and apoptosis levels.[15]

Chang et al have described a Taiwanese infant boy with early-onset cblC disease, heterozygous for c.609G–>A and c.567dupT, who was presymptomatic at newborn screening but later showed life-threatening manifestations. He was the first Asian and was the second case with c.567dupT mutation in the literature. Moreover, all reported cblC patients with the c.609G–>A mutation have been East Asians so far; thus, authors suggest that c.609G–>A should be included in the initial mutation screening tests for a cblC patient in East Asian populations.[16]




Homocystinuria rarely occurs. The prevalence of patients with clinically ascertained CBS deficiency is only 1 in 330,000 worldwide. The molecular epidemiological studies suggest an incidence of around 1 in 10,000 in several European populations.

In Ireland, the frequency is higher, specifically 1 case per 65,000 population based on newborn screening and clinically detected cases. A surprisingly high prevalence of the CBS 833T-C mutation was detected among newborns who did not carry the 844ins68 variant, which is known to neutralize the 833T-CV mutation. This finding led some authors to suggest that the incidence of homocystinuria due to homozygosity for the mutation may be at least 1 case per 20,500 live births in Denmark.

The 0.5% frequency of c.1105 C>T alleles in a predominantly Slavic population of the Czech Republic is similar to the 0.8% frequency in Norwegian newborns or 0.5% shown for 200 North American adult control subjects. Although data from other European populations are lacking, similar frequencies in unrelated Norwegians, Czechs, and North Americans suggest that this variant allele may be of ancient origin and that it may be common in populations of European descent. This high population frequency of mutant CBS alleles may have important consequences for newborn screening. The expected frequency of homocystinuria because of 6 mutations in Norway and 11 mutations in the Czech Republic are similarly high, being 1 in 6,400 and 1 in 15, 500, respectively.[17]

Hypermethioninemia was reported in Korea in 2 compound heterozygous siblings with deficient activity of methionine adenosyltransferase (MAT) in their livers (MAT I/III deficiency). Molecular genetic studies demonstrate that each patient is a compound heterozygote for 2 mutations in MAT1A, the gene that encodes the catalytic subunit that composes MAT I and MAT III. These mutations include a previously known inactivating G378S point mutation and a novel W387X truncating mutation. W387X mutant protein, expressed in E coli and purified, has about 75% of wild-type activity.

Lu et al found an inordinately high prevalence of homocystinuria in the Taiwanese-Austronesian aboriginal tribe of Orchid Island. The prevalence of homocystinuria in the Tao tribe, estimated at approximately 1 in 240 islanders, is the highest known worldwide. All patients were homozygous for the p.D47E mutation. This mutation identified in this population suggests that it interferes with the function and stability of the CBS enzyme.[18, 19]


The disease is more common in males than in females.


This condition is congenital.

Contributor Information and Disclosures

Janette Baloghova, MD, PhD Lecturer, Dermatovenerologist, Medical Faculty, University of PJ Safarik; Department of Dermatovenerology, University Hospital of L Pasteur, Košice, Slovak Republic

Disclosure: Nothing to disclose.


Robert A Schwartz, MD, MPH Professor and Head of Dermatology, Professor of Pathology, Pediatrics, Medicine, and Preventive Medicine and Community Health, Rutgers New Jersey Medical School; Visiting Professor, Rutgers University School of Public Affairs and Administration

Robert A Schwartz, MD, MPH is a member of the following medical societies: Alpha Omega Alpha, New York Academy of Medicine, American Academy of Dermatology, American College of Physicians, Sigma Xi

Disclosure: Nothing to disclose.

Zuzana Baranova, MD, PhD Senior Lecturer, Department of Dermatology, University of PJ Safarik at Kosice, Slovak Republic

Disclosure: Nothing to disclose.

Specialty Editor Board

David F Butler, MD Section Chief of Dermatology, Central Texas Veterans Healthcare System; Professor of Dermatology, Texas A&M University College of Medicine; Founding Chair, Department of Dermatology, Scott and White Clinic

David F Butler, MD is a member of the following medical societies: American Medical Association, Alpha Omega Alpha, Association of Military Dermatologists, American Academy of Dermatology, American Society for Dermatologic Surgery, American Society for MOHS Surgery, Phi Beta Kappa

Disclosure: Nothing to disclose.

Warren R Heymann, MD Head, Division of Dermatology, Professor, Department of Internal Medicine, Rutgers New Jersey Medical School

Warren R Heymann, MD is a member of the following medical societies: American Academy of Dermatology, American Society of Dermatopathology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Chief Editor

Dirk M Elston, MD Professor and Chairman, Department of Dermatology and Dermatologic Surgery, Medical University of South Carolina College of Medicine

Dirk M Elston, MD is a member of the following medical societies: American Academy of Dermatology

Disclosure: Nothing to disclose.

Additional Contributors

Jacek C Szepietowski, MD, PhD Professor, Vice-Head, Department of Dermatology, Venereology and Allergology, Wroclaw Medical University; Director of the Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Poland

Disclosure: Received consulting fee from Orfagen for consulting; Received consulting fee from Maruho for consulting; Received consulting fee from Astellas for consulting; Received consulting fee from Abbott for consulting; Received consulting fee from Leo Pharma for consulting; Received consulting fee from Biogenoma for consulting; Received honoraria from Janssen for speaking and teaching; Received honoraria from Medac for speaking and teaching; Received consulting fee from Dignity Sciences for consulting; .

  1. Mudd SH, Skovby F, Levy HL, et al. The natural history of homocystinuria due to cystathionine beta-synthase deficiency. Am J Hum Genet. 1985 Jan. 37(1):1-31. [Medline].

  2. Finkelstein JD. Inborn errors of sulfur-containing amino acid metabolism. J Nutr. 2006 Jun. 136(6 Suppl):1750S-1754S. [Medline].

  3. Vyletal P, Sokolova J, Cooper DN, et al. Diversity of cystathionine beta-synthase haplotypes bearing the most common homocystinuria mutation c.833T>C: a possible role for gene conversion. Hum Mutat. 2007 Mar. 28(3):255-64. [Medline].

  4. Augoustides-Savvopoulou P, Luka Z, Karyda S, et al. Glycine N -methyltransferase deficiency: a new patient with a novel mutation. J Inherit Metab Dis. 2003. 26(8):745-59. [Medline].

  5. Orendae M, Pronicka E, Kubalska J, et al. Identification and functional analysis of two novel mutations in the CBS gene in Polish patients with homocystinuria. Hum Mutat. 2004 Jun. 23(6):631. [Medline].

  6. Whiteman P, Hutchinson S, Handford PA. Fibrillin-1 misfolding and disease. Antioxid Redox Signal. 2006 Mar-Apr. 8(3-4):338-46. [Medline].

  7. Morel CF, Lerner-Ellis JP, Rosenblatt DS. Combined methylmalonic aciduria and homocystinuria (cblC): phenotype-genotype correlations and ethnic-specific observations. Mol Genet Metab. 2006 Aug. 88(4):315-21. [Medline].

  8. Baumgartner ER, Wick H, Maurer R, et al. Congenital defect in intracellular cobalamin metabolism resulting in homocysteinuria and methylmalonic aciduria. I. Case report and histopathology. Helv Paediatr Acta. 1979. 34(5):465-82. [Medline].

  9. Zavadakova P, Fowler B, Zeman J, et al. CblE type of homocystinuria due to methionine synthase reductase deficiency: clinical and molecular studies and prenatal diagnosis in two families. J Inherit Metab Dis. 2002 Oct. 25(6):461-76. [Medline].

  10. Coelho D, Suormala T, Stucki M, et al. Gene identification for the cblD defect of vitamin B12 metabolism. N Engl J Med. 2008 Apr 3. 358(14):1454-64. [Medline].

  11. Elshorbagy AK, Nurk E, Gjesdal CG, et al. Homocysteine, cysteine, and body composition in the Hordaland Homocysteine Study: does cysteine link amino acid and lipid metabolism?. Am J Clin Nutr. 2008 Sep. 88(3):738-46. [Medline].

  12. Rummel T, Suormala T, Haberle J, et al. Intermediate hyperhomocysteinaemia and compound heterozygosity for the common variant c.677C>T and a MTHFR gene mutation. J Inherit Metab Dis. 2007 Jun. 30(3):401. [Medline].

  13. Bishop L, Kanoff R, Charnas L, Krenzel C, Berry SA, Schimmenti LA. Severe methylenetetrahydrofolate reductase (MTHFR) deficiency: a case report of nonclassical homocystinuria. J Child Neurol. 2008 Jul. 23(7):823-8. [Medline].

  14. Jakubowski H, Boers GH, Strauss KA. Mutations in cystathionine beta-synthase or methylenetetrahydrofolate reductase gene increase N-homocysteinylated protein levels in humans. FASEB J. 2008 Dec. 22(12):4071-6. [Medline].

  15. Richard E, Desviat LR, Ugarte M, Pérez B. Oxidative stress and apoptosis in homocystinuria patients with genetic remethylation defects. J Cell Biochem. 2013 Jan. 114(1):183-91. [Medline].

  16. Chang JT, Chen YY, Liu TT, Liu MY, Chiu PC. Combined methylmalonic aciduria and homocystinuria cblC type of a Taiwanese infant with c.609G>A and C.567dupT mutations in the MMACHC gene. Pediatr Neonatol. 2011 Aug. 52(4):223-6. [Medline].

  17. Miroslav Janošík, Jitka Sokolová, Bohumila Janošíková, Jakub Krijt, Veronika Klatovská, Viktor Kožich. Birth Prevalence of Homocystinuria in Central Europe: Frequency and Pathogenicity of Mutation c.1105C>T (p.R369C) in the Cystathionine Beta-Synthase Gene. J Pediatr. 2009 March. 154(3):431–437.

  18. Lu YH, Huang YH, Cheng LM, et al. Homocystinuria in Taiwan: an inordinately high prevalence in an Austronesian aboriginal tribe, Tao. Mol Genet Metab. 2012 Apr. 105(4):590-5. [Medline].

  19. Lu YH, Cheng LM, Huang YH, Lo MY, Wu TJ, Lin HY, et al. Heterozygous carriers of classical homocystinuria tend to have higher fasting serum homocysteine concentrations than non-carriers in the presence of folate deficiency. Clin Nutr. 2014 Dec 3. pii: S0261-5614(14)00295-7:1-4. [Medline].

  20. Alehan F, Saygi S, Gedik S, Kayahan Ulu EM. Stroke in early childhood due to homocystinuria. Pediatr Neurol. 2010 Oct. 43(4):294-6. [Medline].

  21. Sarov M, Not A, de Baulny HO, Masnou P, Vahedi K, Bousser MG, et al. A case of homocystinuria due to CBS gene mutations revealed by cerebral venous thrombosis. J Neurol Sci. 2014 Jan 15. 336 (1-2):257-9. [Medline].

  22. Goswami JN, Murthy TV, Singh D, Raj V. Cerebral sinovenous thrombosis in a child with homocystinuria. Med J Armed Forces India. 2015 Jul. 71 (Suppl 1):S39-42. [Medline].

  23. Rahman T, Cole EF. Capgras syndrome in homocystinuria. Biol Psychiatry. 2014 Sep 15. 76 (6):e11-2. [Medline].

  24. Colafrancesco G, Di Marzio GM, Abbracciavento G, Stoppioni V, Leuzzi V, Ferrara M. Acute psychosis in an adolescent with undiagnosed homocystinuria. Eur J Pediatr. 2015 Sep. 174 (9):1263-6. [Medline].

  25. Shaker OG, El-Tahlawi SM. Is there a relationship between homocysteine and vitiligo? A pilot study. Br J Dermatol. 2008 Sep. 159(3):720-4. [Medline].

  26. Tallur KK, Johnson DA, Kirk JM, et al. Folate-induced reversal of leukoencephalopathy and intellectual decline in methylene-tetrahydrofolate reductase deficiency: variable response in siblings. Dev Med Child Neurol. 2005 Jan. 47(1):53-6. [Medline].

  27. Sato Y, Iwamoto J, Kanoko T, Satoh K. Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease. Am J Med. 2005 Nov. 118(11):1250-5. [Medline].

  28. Hafidi Z, Berradi S, Handor H, Regragui A, Lezrek M, Daoudi R. Atypical presentation of ectopia lentis in homocystinuria. J Pediatr. 2015 Apr. 166 (4):1091. [Medline].

  29. Gerth C, Morel CF, Feigenbaum A, Levin AV. Ocular phenotype in patients with methylmalonic aciduria and homocystinuria, cobalamin C type. J AAPOS. Dec 2008. 12(6):591-6. [Medline].

  30. Gaillard MC, Matthieu JM, Borruat FX. Retinal dysfunction in combined methylmalonic aciduria and homocystinuria (Cblc) disease: a spectrum of disorders. Klin Monatsbl Augenheilkd. 2008 May. 225(5):491-4. [Medline].

  31. Montalvo LA, Venincasa VD, Aziz HA, Hess D, Berrocal AM. FEVR-Like Presentation of Homocystinuria. Case Rep Ophthalmol Med. 2014. 2014:646351. [Medline].

  32. O'Neill JL, Narahari S, Sane DC, Yosipovitch G. Cardiac manifestations of cutaneous disorders. J Am Acad Dermatol. 2013 Jan. 68(1):156-66. [Medline].

  33. Goswami JN, Murthy SP, Singh D, Raj V. Cerebral sinovenous thrombosis in a child with homocystinuria. Med J Armed Forces India. 2013 Feb. 1-4.

  34. D'Alessandro G, Tagariello T, Piana G. Oral and craniofacial findings in a patient with methylmalonic aciduria and homocystinuria: review and a case report. Minerva Stomatol. 2010 Mar. 59(3):129-37. [Medline].

  35. James SJ, Cutler P, Melnyk S, et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr. 2004 Dec. 80(6):1611-7. [Medline].

  36. Ichinohe A, Kanaumi T, Takashima S, Enokido Y, Nagai Y, Kimura H. Cystathionine beta-synthase is enriched in the brains of Down's patients. Biochem Biophys Res Commun. 2005 Dec 23. 338(3):1547-50. [Medline].

  37. Wilcken DE, Wang J, Sim AS, et al. Asymmetric dimethylarginine in homocystinuria due to cystathionine beta-synthase deficiency: relevance of renal function. J Inherit Metab Dis. 2006 Feb. 29(1):30-7. [Medline].

  38. Snyderman SE. Liver failure and neurologic disease in a patient with homocystinuria. Mol Genet Metab. 2006 Mar. 87(3):210-2. [Medline].

  39. Diana Muacevic-Katanec, Tihomir Kekez, Ksenija Fumic, Ivo Baric, Marijan Merkler, Jasminka Jakic-Razumovic, et al. Spontaneous Perforation of the Small Intestine, a Novel Manifestation of Classical Homocystinuria in an Adult with New Cystathionine ß-synthetaseGene Mutations. Coll. Antropol. 2011, Mar. 35:181-185. [Medline].

  40. Muacevic-Katanec D, Kekez T, Fumic K, et al. Spontaneous perforation of the small intestine, a novel manifestation of classical homocystinuria in an adult with new cystathionine beta-synthetase gene mutations. Coll Antropol. 2011 Mar. 35(1):181-5. [Medline].

  41. Fowler B, Schutgens RB, Rosenblatt DS, et al. Folate-responsive homocystinuria and megaloblastic anaemia in a female patient with functional methionine synthase deficiency (cblE disease). J Inherit Metab Dis. 1997 Nov. 20(6):731-41. [Medline].

  42. Febriani AD, Sakamoto A, Ono H, et al. Determination of total homocysteine in dried blood spots using high performance liquid chromatography for homocystinuria newborn screening. Pediatr Int. 2004 Feb. 46(1):5-9. [Medline].

  43. Bártl J, Chrastina P, Krijt J, Hodík J, Pešková K, Kožich V. Simultaneous determination of cystathionine, total homocysteine, and methionine in dried blood spots by liquid chromatography/tandem mass spectrometry and its utility for the management of patients with homocystinuria. Clin Chim Acta. 2014 Nov 1. 437:211-7. [Medline].

  44. Refsum H, Fredriksen A, Meyer K, et al. Birth prevalence of homocystinuria. J Pediatr. 2004 Jun. 144(6):830-2. [Medline].

  45. Yamasaki-Yashiki S, Tachibana S, Asano Y. Determination of L-methionine using methionine-specific dehydrogenase for diagnosis of homocystinuria due to cystathionine ß-synthase deficiency. Anal Biochem. 2012 Sep 15. 428(2):143-9. [Medline].

  46. Navratil T, Petr M, Senholdova Z, et al. Diagnostic significance of urinary thiodiglycolic acid as a possible tool for studying the role of vitamins B12 and folates in the metabolism of thiolic substances. Physiol Res. 2006 Feb 23. [Medline].

  47. Sen S, Yu J, Yamanishi M, Schellhorn D, Banerjee R. Mapping peptides correlated with transmission of intrasteric inhibition and allosteric activation in human cystathionine beta-synthase. Biochemistry. 2005 Nov 1. 44(43):14210-6. [Medline].

  48. Jakub Krijt, Jana Kopecká, Aleš Hnízda, Stuart Moat, Leo A. J. Kluijtmans, Philip Mayne, et al. Determination of cystathionine beta-synthase activity in human plasma by LC-MS/MS: potential use in diagnosis of CBS deficiency. J Inherit Metab Dis. 2011 February. 34(1):49–55.

  49. Smith DE, Mendes MI, Kluijtmans LA, Janssen MC, Smulders YM, Blom HJ. A liquid chromatography mass spectrometry method for the measurement of cystathionine ß-synthase activity in cell extracts. J Chromatogr B Analyt Technol Biomed Life Sci. 2012 Dec 12. 911:186-91. [Medline].

  50. Chambers AE, McIntosh N, Al-Dirbashi OY, Chakraborty P. Homocysteine analysis in dried blood spots by LC–MS/MS as a second tier test for homocystinuria. Clin Biochem. Oct 2014. 47(15):140.

  51. Scherer EB, Stefanello FM, Mattos C, Netto CA, Wyse AT. Homocysteine reduces cholinesterase activity in rat and human serum. Int J Dev Neurosci. 2007 Jun. 25(4):201-5. [Medline].

  52. Debray FG, Boulanger Y, Khiat A, et al. Reduced brain choline in homocystinuria due to remethylation defects. Neurology. 2008 Jul 1. 71(1):44-9. [Medline].

  53. Sosvorová L, Bešťák J, Bičíková M, Mohapl M, Hill M, Kubátová J, et al. Determination of homocysteine in cerebrospinal fluid as an indicator for surgery treatment in patients with hydrocefalus. Physiol Res. 2014 Sep 4. 63 (4):521-7. [Medline].

  54. Longo D, Fariello G, Dionisi-Vici C, et al. MRI and 1H-MRS findings in early-onset cobalamin C/D defect. Neuropediatrics. 2005 Dec. 36(6):366-72. [Medline].

  55. Poloni S, Schweigert Perry ID, D'Almeida V, Schwartz IV. Does phase angle correlate with hyperhomocysteinemia? A study of patients with classical homocystinuria. Clin Nutr. 2013 Jun. 32(3):479-80. [Medline].

  56. Zong Y, Liu N, Zhao Z, Kong X. Prenatal diagnosis using genetic sequencing and identification of a novel mutation in MMACHC. BMC Med Genet. 2015 Jul 7. 16:48. [Medline].

  57. Gahl WA, Bernardini I, Chen S, et al. The effect of oral betaine on vertebral body bone density in pyridoxine-non-responsive homocystinuria. J Inherit Metab Dis. 1988. 11(3):291-8. [Medline].

  58. Lawson-Yuen A, Levy HL. The use of betaine in the treatment of elevated homocysteine. Mol Genet Metab. 2006 Jul. 88(3):201-7. [Medline].

  59. Singh RH, Kruger WD, Wang L, et al. Cystathionine beta-synthase deficiency: effects of betaine supplementation after methionine restriction in B6-nonresponsive homocystinuria. Genet Med. 2004 Mar-Apr. 6(2):90-5. [Medline].

  60. Sakamoto A, Sakura N. Limited effectiveness of betaine therapy for cystathionine beta synthase deficiency. Pediatr Int. 2003 Jun. 45(3):333-8. [Medline].

  61. Yaghmai R, Kashani AH, Geraghty MT, et al. Progressive cerebral edema associated with high methionine levels and betaine therapy in a patient with cystathionine beta-synthase (CBS) deficiency. Am J Med Genet. 2002 Feb 15. 108(1):57-63. [Medline].

  62. Liu Y, Wang Q, Li X, Ding Y, Song J, Yang Y. First Chinese case of successful pregnancy with combined methylmalonic aciduria and homocystinuria, cblC type. Brain Dev. 2015 Mar. 37 (3):286-91. [Medline].

  63. Tada H, Takanashi J, Barkovich AJ, et al. Reversible white matter lesion in methionine adenosyltransferase I/III deficiency. AJNR Am J Neuroradiol. 2004 Nov-Dec. 25(10):1843-5. [Medline].

  64. Bass HN, LaGrave D, Mardach R, Cederbaum SD, Fuster CD, Chetty M. Spontaneous pneumothorax in association with pyridoxine-responsive homocystinuria. J Inherit Metab Dis. 1997 Nov. 20(6):831-2. [Medline].

  65. Zaidi SH, Faiyaz-Ul-Haque M, Shuaib T, et al. Clinical and molecular findings of 13 families from Saudi Arabia and a family from Sudan with homocystinuria. Clin Genet. 2012 Jun. 81(6):563-70. [Medline].

  66. Kozich V, Sokolová J, Klatovská V, Krijt J, Janosík M, Jelínek K, et al. Cystathionine beta-synthase mutations: effect of mutation topology on folding and activity. Hum Mutat. 2010 Jul. 31(7):809-19. [Medline]. [Full Text].

  67. Scriver CR, Beaudet AL, Sly WS. The Metabolic and Molecular Bases of Inherited Diseases. 7th ed. New York, NY: McGraw-Hill; 1995.

  68. Lu YH, Cheng LM, Huang YH, Lo MY, Wu TJ, Lin HY, et al. Heterozygous carriers of classical homocystinuria tend to have higher fasting serum homocysteine concentrations than non-carriers in the presence of folate deficiency. Clin Nutr. 2014 Dec 3. 1-4. [Medline].

Simplified picture showing homocysteine involvement in different metabolic pathways, as well as the role of vitamins B-6, B-12, and folate as a co-factors in this pathway.
All material on this website is protected by copyright, Copyright © 1994-2016 by WebMD LLC. This website also contains material copyrighted by 3rd parties.